2018
DOI: 10.1016/j.bmcl.2018.05.014
|View full text |Cite
|
Sign up to set email alerts
|

Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
27
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(27 citation statements)
references
References 17 publications
0
27
0
Order By: Relevance
“…FASN is transcriptionally regulated by LXR (40), FXR (41), and retinol A (42). Functionally, decreased FASN expression is associated with inhibition of proliferation (43), providing a potential explanation for the regionally specific proliferation response observed in the current study. Furthermore, our results, when considered with recent studies of rodent model of respiratory disease, provide novel evidence for the consideration of LXR agonists as potential therapeutic candidates for the prevention and/or treatment of preterm VILI.…”
Section: Discussionmentioning
confidence: 51%
“…FASN is transcriptionally regulated by LXR (40), FXR (41), and retinol A (42). Functionally, decreased FASN expression is associated with inhibition of proliferation (43), providing a potential explanation for the regionally specific proliferation response observed in the current study. Furthermore, our results, when considered with recent studies of rodent model of respiratory disease, provide novel evidence for the consideration of LXR agonists as potential therapeutic candidates for the prevention and/or treatment of preterm VILI.…”
Section: Discussionmentioning
confidence: 51%
“…Lu et al have synthesized several FASN inhibitors recently using a structure-based approach guided by X-ray crystallography approach (51). Among them, compound 34 showed a high FASN inhibitory potential and favorable pharmacological features; in addition, it strongly inhibited cell proliferation in several cancer cell lines including A2780 (ovarian), PC3M (prostate), LNCaP (prostate), OCI LY1 (lymphoma), MV4-11 (leukemia/lymphoma/myeloma), H460 (lung), A549 (lung), and MDA-MB-468 (breast), becoming an interesting candidate for future studies (51).…”
Section: Inhibition Of Fatty Acid Synthase In Human Hepatocellular Camentioning
confidence: 99%
“…FASN is highly expressed in ovarian cancer tissues and is associated with poor prognosis and survival rate (56). Because the majority of cancers rely on the FASN-mediated de novo fatty acid synthesis pathway, FASN could be an attractive therapeutic target, and inhibition of FASN has shown antitumor effects in ovarian cancer (25,57). In tumor cell lines, FASN overexpression was found to cause chemotherapy resistance induced by culture in drug-containing media.…”
Section: Fatty Acid Synthase (Fasn)mentioning
confidence: 99%